Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore
NCT07617272
Summary
The PARIS-BIO study evaluates whether a novel genomic biomarker, the PCAI ImmunoScore, can predict the response to neoadjuvant treatment with Darolutamide in patients with high-risk localized or locally advanced prostate cancer. Patients will receive Darolutamide monotherapy for 90-120 days prior to radical prostatectomy. The study aims to validate if the biomarker can identify patients who achieve Minimal Residual Disease (MRD) at the time of surgery.
Eligibility
Inclusion Criteria: * Biopsy-confirmed high-risk prostate cancer defined as: Global ISUP score \> 3 with any MRI PI-RADS score OR Global ISUP score = 3 with MRI PI-RADS score = 5 * Candidate for radical prostatectomy * Clinical prostate MRI not older than 3 months at screening * ECOG performance status score of 0 or 1 * Able to receive Darolutamide for 90-120 days * Signed informed consent form * Willingness to use contraception if sexually active Exclusion Criteria: * Metastatic (M1) or node-positive (N2) disease * Prior treatment with androgen receptor antagonists * Prior treatment with gonadotropin-releasing hormone (GnRH) * History of prior systemic or local therapy for prostate cancer (including radiation and focal therapy) * Major surgery \<4 weeks prior to inclusion
Conditions2
Interventions1
Related trials
- A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. — Bayer
- Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Swiss Cancer Institute
- Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC — Erasmus Medical Center
- Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer — Xijing Hospital
- Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors. — Spanish Oncology Genito-Urinary Group
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer — Karolinska Institutet
- Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse — UNICANCER
- TT-702 in Patients With Advanced Solid Tumours. — Cancer Research UK
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07617272